NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/22/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,418.15 mln
Float113 mln
Earnings Date07/29/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
92.33
Transformational upside
Relative Strength
36
/ 100
Underperforming
Debt / Equity
0.00
Debt-free
ROE
-67.55
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Viking Therapeutics is a San Diego-based company founded in 2012 that researches and develops new medicines targeting hormonal and metabolic diseases. The company has several drugs in clinical testing, addressing conditions such as liver disease, muscle loss following hip fractures, and rare genetic disorders. Its most advanced treatments work by selectively targeting specific receptors in the body, aiming to deliver therapeutic benefits while minimizing unwanted side effects.
